Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
(2021)
Journal Article
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., Tarr, A. W., Nightingale, J., Norrish, A. R., Ikram, A., Marson, B., Craxford, S. J., Kelly, A., Aithal, G. P., Vijay, A., Tighe, P. J., Ball, J. K., Valdes, A. M., & Ollivere, B. J. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational Medicine, 13(609), Article eabj0847. https://doi.org/10.1126/scitranslmed.abj0847
Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necess... Read More about Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.